The first was identified as an antibody-based therapeutic platform company, the second an AI diagnostic solution startup, and the third a cell therapy specialist. Additionally, a next-generation vaccine developer and a gene-editing new drug venture were included in the list. All of them are attracting investor attention with strong pipelines and unique technological capabilities. In particular, these companies are achieving rapid growth based on domestic R&D infrastructure and government support. They are accelerating their entry into the international arena through joint research with global big pharma, technology licensing collaborations, and expansion of overseas clinical networks. Some companies have already entered the Pre-IPO stage and are highly anticipated in the capital market. However, the growth of these startups is accompanied by realistic challenges such as the regulatory environment, funding, and barriers to global market entry. Nevertheless, the prevailing assessment is that Korean bio startups possess the potential to leap forward as unicorn companies.